Ovid Therapeutics/OVID

$3.63

-1.35%
-
1D1W1MYTD1YMAX

About Ovid Therapeutics

Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing medicines for patients and families living with epilepsies and seizure-related neurological disorders. The Company is developing OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. The Company’s genetic research programs include OV815 and OV825 and OV882. OV815 focuses on the mutations associated with KIF1A-associated neurological disorder (KAND). OV825 has advanced to candidate lead identification for the rare neurodevelopmental condition HNRNPH2. OV882 is a short hairpin RNA that the Company is evaluating as a potential disease-modifying gene therapy for Angelman syndrome. OV329 is an investigational, next-generation GABA-AT inhibitor that the Company is developing for the treatment of adult and pediatric epilepsy disorders.

Ticker

OVID

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeremy Levin

Employees

39

Headquarters

New york, United States
Website
ovidrx.com

OVID Metrics

BasicAdvanced
$260.1M
Market cap
-
P/E ratio
-$0.69
EPS
0.74
Beta
-
Dividend rate

What the Analysts think about OVID

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 4 analysts.
99.72% upside
High $11.00
Low $4.00
$3.63
Current price
$7.25
Average price target

OVID Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-11,200% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$100K
∞%
Net income
$-11.2M
-9.68%
Profit margin
-11,200%
-∞%

OVID Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.16%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.16
-$0.19
-$0.18
-$0.16
-
Expected
-$0.18
-$0.17
-$0.20
-$0.19
-$0.05
Surprise
-12.21%
10.95%
-12.02%
-15.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Ovid Therapeutics stock

Buy or sell Ovid Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing